Regeneron Pharmaceuticals, Inc.
REGN
$766.66
-$24.15-3.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.52% | 1.84% | |||
| Total Other Revenue | 20.38% | 7.78% | |||
| Total Revenue | 3.46% | 2.14% | |||
| Cost of Revenue | 10.72% | 2.29% | |||
| Gross Profit | -4.78% | 1.97% | |||
| SG&A Expenses | 17.82% | 3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 100.00% | -- | |||
| Total Operating Expenses | 12.91% | 2.25% | |||
| Operating Income | -19.04% | 1.87% | |||
| Income Before Tax | -40.81% | 16.11% | |||
| Income Tax Expenses | -34.36% | 138.63% | |||
| Earnings from Continuing Operations | -42.15% | 4.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.15% | 4.92% | |||
| EBIT | -19.04% | 1.87% | |||
| EBITDA | -16.28% | 1.80% | |||
| EPS Basic | -41.76% | 6.43% | |||
| Normalized Basic EPS | 61.94% | 0.64% | |||
| EPS Diluted | -42.31% | 6.32% | |||
| Normalized Diluted EPS | 60.39% | 0.50% | |||
| Average Basic Shares Outstanding | -0.68% | -1.43% | |||
| Average Diluted Shares Outstanding | 0.28% | -1.29% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 0.76% | -0.06% | |||